Evidence map›Paper›PMID 42112232›Full record

ArticleFrontiers in molecular neuroscience2026

Optimizing single-session CBT delivery in an 8-session longitudinal therapeutic assessment (FRAX-TA) for women with

Federica Alice Maria Montanaro, Giuseppina Spano, Randi J Hagerman, Giancarlo Logroscino, Andrea Bosco

Abstract read
In one paragraph

Article in Frontiers in molecular neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Federica Alice Maria MontanaroDepartment of Education, Psychology, Communication, University of Bari Aldo Moro, Bari, Italy.
Giuseppina SpanoDepartment of Psychology and Health Science, Pegaso University, Naples, Italy.
Randi J HagermanUC Davis MIND Institute, UC Davis Health, Sacramento, CA, United States.
Giancarlo LogroscinoDepartment of Clinical Research in Neurology, Center for Neurodegenerative Diseases and the Aging Brain, University of Bari Aldo Moro/Pia Fond. Card. G. Panico, Tricase, Italy.
Andrea BoscoDepartment of Education, Psychology, Communication, University of Bari Aldo Moro, Bari, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Therapeutic Assessment (TA) is a client-centered approach that uses psychological evaluation to promote therapeutic change. While TA has shown benefits across populations, its application to genetically at-risk groups remains limited. Women with the Methods: Eighty-one Italian women with genetically confirmed PM (M age = 50.5 ± 9.41) completed an 8-week TA protocol based on the Cognitive Behavioral Assessment for Outcome Evaluation (CBA-VE). Participants were randomized into four groups receiving the PA during the 4th, 6th, 8th, or 10th week from baseline. Mixed-design Bayesian ANOVAs assessed changes across timepoints (baseline, post-PA, follow-up) and the effect of the PA timing on the five CBA-OE psychological domains (anxiety, wellbeing, perception of positive change, depression, and psychological distress). An anonymous feedback questionnaire evaluated participant experiences. Results: Participants showed significant reductions in the CBA-VE anxiety, depression, and distress scores. The PA had both immediate and delayed effects, particularly for depression and anxiety. Mid-phase delivery led to more stable improvements in CBA-VE perceived positive change. Qualitative feedback indicated high satisfaction and emotional support. Conclusion: FRAX-TA appears effective for women with the PM, providing therapeutic benefit even without ongoing treatment. Findings underscore the added value of SS-CBT within assessment and suggest that repeated sessions may enhance symptom recognition and prompt further care. Future studies should include control groups, larger samples, and examine personalized timing to optimize outcomes.

Indexed as

cognitive behavioral therapyFMR1 premutationFragile X DisordersFragile X Premutation Associated ConditionsFragile X SyndromeFXANDsingle-session interventiontherapeutic assessment

Identifiers

PMID42112232
PMCPMC13152860

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.